—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

Dr. Sandip Patel discusses findings from a real-world study of biomarker testing in early-stage resected non-small cell lung ...

Cancer is often caused by genetic mutations, which can lead to abnormal cell growth in the body. One type is called the KRAS G12C mutation, which happens in the KRAS protein.[1] KRAS acts as the ...

Pharmacodynamic Activity of [18F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2-Mutated Breast Cancer Receiving Talazoparib We extracted real-world ...

Biomarker testing is critical for determining optimal therapy early in the non–small lung cancer (NSCLC) treatment process, but research shows uneven insurance coverage of these tests and inconsistent ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated ...

Jonathan Thompson, MD, MS, explains how financial, insurance, and socioeconomic barriers limit equitable access to biomarker testing and advanced therapies, underscoring the need for provider advocacy ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated ...

The study will assess safety, preliminary efficacy, and biomarker correlations, potentially paving a path toward accelerated development. The biomarker-focused trial will target high-risk NSCLC ...